Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab

<b><i>Background:</i></b> Bevacizumab, a vascular endothelial growth factor (VEGF) monoclonal antibody commonly used for the treatment of various cancers, is often associated with adverse cardiovascular effects such as hypertension, cardiac and cerebral ischemia, thrombosis,...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Doan T. M. Ngo, Trent Williams, Sophie Horder, Leonard Kritharides, Janette Vardy, Hiren Mandaliya, Ina I. C. Nordman, James Lynam, Tony Bonaventura, Aaron L. Sverdlov
Formato: Artigo
Idioma:Inglês
Publicado: MDPI AG 2020-08-01
Series:Journal of Clinical Medicine
Assuntos:
bevacizumab
VEGF inhibitors
cardiovascular risk
complications
outcomes
Acceso en liña:https://www.mdpi.com/2077-0383/9/8/2664
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares